Tyrosine kinases in inflammatory dermatologic disease - 28/07/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Abstract |
Tyrosine kinases (TKs) are enzymes that catalyze the phosphorylation of tyrosine residues on protein substrates. They are key components of signaling pathways that drive an array of cellular responses including proliferation, differentiation, migration, and survival. Specific TKs have recently been identified as critical to the pathogenesis of several autoimmune and inflammatory diseases. Small-molecule inhibitors of TKs are emerging as a novel class of therapy that may provide benefit in certain patient subsets. In this review, we highlight TK signaling implicated in inflammatory dermatologic diseases, evaluate strategies aimed at inhibiting these aberrant signaling pathways, and discuss prospects for future drug development.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune, dermatology, dermatomyositis, fibrosis, inflammatory, pemphigus, phosphorylation, psoriasis, tyrosine kinase
Abbreviations used : Abl, DM, Dsg, EGF, EGFR, FDA, FLT3, GVHD, HCT, IFN, JAK, MAPK, NSF, PDGF, PDGFR, PV, SLE, Src, SSc, TGF, TK, TLR, VEGF, VEGFR
Plan
Supported by the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01-AR-054822 (Dr Robinson); the Department of Veterans Affairs (Drs Robinson and Chung); and the Scleroderma Research Foundation (Dr Chung). |
|
Conflicts of interest: None declared. |
Vol 65 - N° 2
P. 389-403 - août 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?